|Title:||Solid orally administerable raloxifene hydrochloride pharmaceutical formulation|
|Abstract:||This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.|
|Inventor(s):||Gibson; Lowell L. (Greenwood, IN), Hartauer; Kerry J. (Indianapolis, IN), Stowers; Julian L. (Indianapolis, IN), Sweetana; Stephanie A. (Bloomington, IN), Thakkar; Arvind L. (Indianapolis, IN)|
|Assignee:||Eli Lilly and Company (Indianapolis, IN)|
Patent Claim Types:|
see list of patent claims
|Formulation; Compound; Composition; Dosage form;|
Field: Not categorized
Back Citations: 9th percentile
Forward Citations: 6th percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.